[go: up one dir, main page]

MX2025009371A - Forma cristalina de derivado de sulfonamida y metodo de preparacion para ello - Google Patents

Forma cristalina de derivado de sulfonamida y metodo de preparacion para ello

Info

Publication number
MX2025009371A
MX2025009371A MX2025009371A MX2025009371A MX2025009371A MX 2025009371 A MX2025009371 A MX 2025009371A MX 2025009371 A MX2025009371 A MX 2025009371A MX 2025009371 A MX2025009371 A MX 2025009371A MX 2025009371 A MX2025009371 A MX 2025009371A
Authority
MX
Mexico
Prior art keywords
preparation
crystalline form
method therefor
sulfonamide derivative
present disclosure
Prior art date
Application number
MX2025009371A
Other languages
English (en)
Inventor
Xiaosi Hu
Lingfeng You
Jun Feng
Feng He
Junran Yang
Zhenxing Du
Original Assignee
Jiangsu Hengrui Pharmaceuticals Co Ltd
Shanghai hengrui pharmaceutical co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Pharmaceuticals Co Ltd, Shanghai hengrui pharmaceutical co ltd filed Critical Jiangsu Hengrui Pharmaceuticals Co Ltd
Publication of MX2025009371A publication Critical patent/MX2025009371A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente divulgación se refiere a una forma cristalina de un derivado de sulfonamida, y a un método de preparación del mismo; específicamente, la presente divulgación provee una nueva forma cristalina de un compuesto según el representado por la fórmula (1), y un método de preparación de la misma.
MX2025009371A 2023-02-10 2025-08-08 Forma cristalina de derivado de sulfonamida y metodo de preparacion para ello MX2025009371A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202310107569 2023-02-10
PCT/CN2024/076561 WO2024165035A1 (zh) 2023-02-10 2024-02-07 一种磺酰胺衍生物结晶形式及其制备方法

Publications (1)

Publication Number Publication Date
MX2025009371A true MX2025009371A (es) 2025-09-02

Family

ID=92262071

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2025009371A MX2025009371A (es) 2023-02-10 2025-08-08 Forma cristalina de derivado de sulfonamida y metodo de preparacion para ello

Country Status (7)

Country Link
EP (1) EP4663635A1 (es)
KR (1) KR20250143814A (es)
CN (1) CN120569381A (es)
AU (1) AU2024217108A1 (es)
MX (1) MX2025009371A (es)
TW (1) TW202434600A (es)
WO (1) WO2024165035A1 (es)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201510019D0 (en) 2015-06-09 2015-07-22 Cancer Therapeutics Crc Pty Ltd Compounds
GB201713962D0 (en) 2017-08-31 2017-10-18 Ctxt Pty Ltd Compounds
MX2020007131A (es) 2017-11-29 2021-01-08 Epizyme Inc Inhibidores de histona acetiltransferasa de la familia myst.
GB201810092D0 (en) 2018-06-20 2018-08-08 Ctxt Pty Ltd Compounds
GB201810581D0 (en) 2018-06-28 2018-08-15 Ctxt Pty Ltd Compounds
EP3959202B1 (en) 2019-04-25 2023-08-16 Bayer Aktiengesellschaft Acyl sulfonamides for treating cancer
AU2020296361A1 (en) * 2019-06-18 2022-01-06 Ctxt Pty Ltd Benzisoxazole sulfonamide derivatives
AU2020295006B2 (en) 2019-06-19 2023-11-09 Ctxt Pty Ltd Cycloalkyl and heterocycloalkyl benzisoxazole sulfonamide derivatives
CA3225068A1 (en) * 2021-07-05 2023-01-12 Hangzhou Innogate Pharma Co., Ltd. Compound serving as kat6 inhibitor
JP2024529068A (ja) * 2021-08-10 2024-08-01 江蘇恒瑞医薬股▲ふん▼有限公司 スルファミド誘導体、その調製方法及びその医薬的使用
CA3237830A1 (en) * 2021-11-16 2023-05-25 Insilico Medicine Ip Limited Lysine acetyltransferase 6a (kat6a) inhibitors and uses thereof
CN116621859A (zh) * 2022-02-18 2023-08-22 山东轩竹医药科技有限公司 三并环类kat6抑制剂

Also Published As

Publication number Publication date
CN120569381A (zh) 2025-08-29
EP4663635A1 (en) 2025-12-17
WO2024165035A1 (zh) 2024-08-15
AU2024217108A1 (en) 2025-09-18
TW202434600A (zh) 2024-09-01
KR20250143814A (ko) 2025-10-02

Similar Documents

Publication Publication Date Title
ZA202308002B (en) Pyrimidopyran compound
CR20230496A (es) Compuestos heterocíclicos
SA523451905B1 (ar) Cdk2 مركبات بيريميدينيل-بيرازول بها استبدال كمثبطات
PH12023553237A1 (en) Spiroindolinone compounds as kv1.3 potassium shaker channel blockers
MX2025005591A (es) Cristal de derivado de piperazina sustituido y metodo de preparacion del mismo
MX2025001749A (es) Compuesto como inhibidor del canal de sodio dependiente del voltaje
ZA202301378B (en) Solid form of compound
MX2025001765A (es) Derivados deuterados de pirimidin-2-il sulfonamida
MX2023000970A (es) Metodo de preparacion de aminofuranos.
PH12022550985A1 (en) 3-n-cyclopropylmethyl-2-fluorobenzamide compound, preparation method therefor and use thereof
DE602004020667D1 (en) Prostaglandinsynthese
WO2021016220A3 (en) Synthesis of substituted furans
WO2020016302A8 (en) A xinafoate salt of a jak inhibiting compound
MX2024005066A (es) Compuestos de cd73.
WO2020003272A8 (en) An improved process for the preparation of venetoclax
MX2025009371A (es) Forma cristalina de derivado de sulfonamida y metodo de preparacion para ello
MX2025000464A (es) Forma cristalina de un esteroide neuroactivo
MX2024013227A (es) Proceso para la produccion de intermediarios de estetrol
EP1390343A4 (en) NOVEL RETINOID DERIVATIVES, METHODS FOR PREPARING THESE COMPOUNDS, AND ANTI-CANCER PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
MX2024008959A (es) Forma cristalina de derivado de isoindolina que contiene azufre.
MX2023002068A (es) Nuevos compuestos que tienen actividad inhibidora sobre el receptor de prostaglandina e2 y usos de los mismos.
MX2023005713A (es) Nuevo proceso para la elaboracion de derivados de tetrazol.
MX2021012690A (es) Formas cristalinas y metodos para producir formas cristalinas de un compuesto.
MX2025007682A (es) Procedimiento para la preparacion de derivados de acido isoxazolincarboxilico
MX2023015302A (es) Metodo para producir derivados del acido isoxazolincarboxilico.